GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

Exclusion Criteria

• •Grade ≥1 peripheral neuropathy (CTCAE grade ≥1) or any of the first 4 items of FACT/GOG-Ntx ≥1;
• •There are risk factors for peripheral neuropathy (excluding peripheral neuropathy caused by chemotherapy).
• •History of another malignant tumors (except breast cancer)
• •Symptoms such as muscle pain in the limbs that interfere with the evaluate of peripheral neuropathy;
• •Uncontrolled cardiovascular and cerebrovascular system diseases or hypertension
• •Active infections that require systematic treatment, including bacteria, fungi or viruses, within one week before first study drug use; Or infectious diarrhea occurred within 4 weeks before the first study drug use;
• •Hereditary abnormal glycolipid metabolism, HIV infection or known Acquired Immune Deficiency Syndrome (AIDS); Positive syphilis antibody, active hepatitis B, active hepatitis C